Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Perrigo Company plc

Cost of Revenue Trends in Pharma: Dr. Reddy's vs. Perrigo

__timestampDr. Reddy's Laboratories LimitedPerrigo Company plc
Wednesday, January 1, 2014563690000002613100000
Thursday, January 1, 2015627860000002891500000
Friday, January 1, 2016624270000003228800000
Sunday, January 1, 2017624530000002966700000
Monday, January 1, 2018657240000002900200000
Tuesday, January 1, 2019704210000003064100000
Wednesday, January 1, 2020805910000003248100000
Friday, January 1, 2021866450000002722500000
Saturday, January 1, 20221005510000002996200000
Sunday, January 1, 2023429070000002975200000
Monday, January 1, 2024115557000000
Loading chart...

Cracking the code

Analyzing Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Dr. Reddy's Laboratories Limited and Perrigo Company plc, two prominent players, showcase intriguing trends in their cost of revenue from 2014 to 2024. Dr. Reddy's Laboratories, based in India, has seen a significant increase in its cost of revenue, peaking in 2024 with a staggering 115% rise from its 2014 figures. This growth reflects the company's expanding global footprint and investment in research and development. In contrast, Perrigo Company, headquartered in Ireland, maintains a more stable cost structure, with fluctuations of less than 25% over the same period. This stability highlights Perrigo's focus on efficiency and cost management. Notably, 2023 data for Dr. Reddy's shows a dip, possibly indicating strategic shifts or market challenges. Missing data for 2024 suggests ongoing developments worth monitoring.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025